In deciding what products to include in a drug plan – public or private – payers make an assessment of the “value” offered by a product. When doing their assessments, Health Technology Agencies (HTA) and public drug plan managers take a more narrow approach in assessing “value” compared to the approach that a private payer needs to take. As a result, HTA assessments can overlook benefits that are important to patients, employers and, thus, private payers. While there are components of HTA assessments that are of interest to private payers, relying on an HTA assessment and overlooking these additional benefits can undermine the intended role of a private drug plan in an employer’s overall benefits and compensation package.